Interpace Biosciences (IDXG) Q2 2024 earnings summary

Executive summary

• Q2 2024 net revenue increased 9% year-over-year to $12.0 million, with test volume up 12% to all-time highs, driven by proprietary molecular diagnostic tests.

• Operating income from continuing operations rose to $2.3 million in Q2 2024 from $0.8 million in Q2 2023.

• Net income for Q2 2024 was $2.1 million, up from $0.2 million in Q2 2023.

• Cash collections reached $11.0 million, a 7% increase year-over-year, with profitability and positive cash flow maintained.

• Sixteenth consecutive quarter of year-over-year volume growth, supported by strong physician adoption.

Financial highlights

• Gross profit margin remained stable at 62% for Q2 2024 and 60% for the first half of 2024.

• Adjusted EBITDA for Q2 2024 was $2.4 million, up from $1.3 million in Q2 2023.

• Cash and cash equivalents were $2.0 million as of June 30, 2024, with current assets of $10.2 million and current liabilities of $19.0 million.

• Operating cash flow for the first half of 2024 was $1.3 million.

• Operating income rose to $2.2 million from $0.8 million in the prior-year quarter.

Outlook and guidance

• Management anticipates current cash and forecasted receipts will be sufficient to meet anticipated cash requirements through the next twelve months.

• Company expects to maintain positive cash flow and profitability, supported by operational efficiencies and market demand.

• The company continues to explore strategic alternatives and additional funding sources due to capital constraints and delisting from Nasdaq.